EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, Docking Studies, and Investigation of Dual EGFR/VEGFR‐2 Inhibitory Potentials of New Pyrazole and Pyrazolopyridine Derivatives

Shimaa M Alhamaky, Nadia A Khalil, Amr K A Bass, Nada Osama, Marwa S A Hassan iD

Drug Development Research · 2025

DOI: 10.1002/ddr.70056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von Shimaa M Alhamaky und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Chemistry Department, Faculty of Pharmacy, Menoufia University, Menoufia, Egypt. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Pyrazoles, ErbB Receptors, Pyridines. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The anticancer potential of certain newly synthesized pyrazole and pyrazolopyridine derivatives has been estimated. NCI 60 cancer cells cytotoxic screening pointed out compounds 3e and 3f as the highest cytotoxic agents with % mean growth inhibition of 67.69% and 87.34%, respectively. The five dose outcomes outlined 3f as the most potent cytotoxic agent with promising MG‐MID GI 50 = 3.3 µM when compared to erlotinib (MG‐MID GI 50 = 7.68 µM). In the in vitro assays, compounds 3d, 3e, 3f, and 4a demonstrated dual inhibitory potential on EGFR WT and VEGFR‐2 with IC 50 range of 0.066−0.184 µM and 0.102−0.418 µM, respectively. The best dual EGFR/VEGRF‐2 inhibitory effect was shown by the compound 3f . Moreover, the latter compound stopped the cell cycle at the G1/S phase. Also, it greatly boosted total apoptosis, including early and late apoptosis, by 54.5‐ and 84.7‐fold, respectively, which supposes HCT‐116 cell death via inducing apoptosis. This was confirmed by the elevation of the BAX and caspase‐3 levels, and the decreased BCL‐2 level. Moreover, the safety of the most active compound 3f was assessed and the results showed promising selectivity of compound 3f toward HCT‐116 over FHC (selectivity index [SI]: 20.84) when compared to erlotinib (SI: 3.42). Finally, compound 3f demonstrated efficient binding to both EGFR and VEGFR‐2 enzymes, which could explain the sufficient inhibition level of each enzyme.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor Receptor-2PyrazolesErbB ReceptorsPyridinesAntineoplastic AgentsProtein Kinase InhibitorsHumansMolecular Docking SimulationDrug DesignApoptosisCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHCT116 CellsStructure-Activity Relationship

Stichwörter der Autor:innen

dual EGFR/VEGFR‐2 inhibitorspyrazolepyrazolopyridinesynthesis

Substanzen

Vascular Endothelial Growth Factor Receptor-2PyrazolesErbB ReceptorsPyridinesEGFR protein, humanAntineoplastic AgentsKDR protein, humanpyrazolopyridineProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Pharmaceutical Chemistry Department, Faculty of Pharmacy, Menoufia University, Menoufia, Egypt.
  • Pharmaceutical Chemistry Department, Faculty of Pharmacy, Menoufia National University, Menoufia, Egypt.
  • Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
  • Biochemistry Department, Faculty of Pharmacy, Menoufia University, Menoufia, Egypt.

ORCID-Profile: Marwa S A Hassan

Zitieren

APA

Alhamaky, S. M., Khalil, N. A., Bass, A. K. A., Osama, N., & Hassan, M. S. A. (2025). Design, Synthesis, Docking Studies, and Investigation of Dual EGFR/VEGFR‐2 Inhibitory Potentials of New Pyrazole and Pyrazolopyridine Derivatives. Drug Development Research. https://doi.org/10.1002/ddr.70056

Vancouver

Alhamaky SM, Khalil NA, Bass AKA, Osama N, Hassan MSA. Design, Synthesis, Docking Studies, and Investigation of Dual EGFR/VEGFR‐2 Inhibitory Potentials of New Pyrazole and Pyrazolopyridine Derivatives. Drug Development Research. 2025. doi:10.1002/ddr.70056

BibTeX
@article{Alhamaky2025,
  author = {Alhamaky, Shimaa M and Khalil, Nadia A and Bass, Amr K A and Osama, Nada and Hassan, Marwa S A},
  title = {Design, Synthesis, Docking Studies, and Investigation of Dual EGFR/VEGFR‐2 Inhibitory Potentials of New Pyrazole and Pyrazolopyridine Derivatives},
  journal = {Drug Development Research},
  year = {2025},
  doi = {10.1002/ddr.70056}
}
Kostenlos starten →